Drug-eluting Stenting Versus Medical Treatment Alone for Patients With Extracranial Vertebral Artery Stenosis

Prof. Hugh Stephen Markus

Study started April 2023, Ongoing Identifier: NCT05885932 +Stenting+Versus+Medical+Treatment+Alone+for+Patients+With+Extracranial+Vertebral+Artery+Stenosis&draw=2&rank=1

The drug-eluting stenting versus medical therapy alone for patients with extracranial vertebral artery stenosis (VISTA) trial, is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit patients with 3 months stroke or TIA caused by 70-99% stenosis of extracranial vertebral artery (V1-2 segments). Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus stenting. Primary outcome is a composite of any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year.  Recruitment is expected to be finished by Sep, 2025. The first stage of the trial is scheduled to complete in 2027.


Extracranial vertebral artery stenosis, Drug-eluting stenting, Best medical treatment, Ischemic stroke.

Relevant article:

Markus HS, Larsson SC, et al. VIST Investigators. Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial. Neurology. 2017 Sep 19;89(12):1229-1236. doi: 10.1212/WNL.0000000000004385IF: 9.9 Q1 . Epub 2017 Aug 23. PMID: 28835400; PMCID: PMC5606920.

Turan TN, Zaidat OO, et al. Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. Neurology. 2022 Mar 22;98(12):486-498. doi: 10.1212/WNL.0000000000200030IF: 9.9 Q1 . PMID: 35314513; PMCID: PMC8967328.

Compter A, et al. VAST investigators. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol. 2015 Jun;14(6):606-14. doi: 10.1016/S1474-4422(15)00017-4. Epub 2015 Apr 20. PMID: 25908089.

Prof. Huaizhang Shi
Prof. Liqun Jiao
Dalian Central HospitalProf.Li Di
The First Affiliated Hospital of Dalian Medical UniversityProf.Wang Feng
Zhongda Hospital affiliated to Southeast UniversityProf.Deng Gang
Zhangzhou Hospital, Fujian ProvinceProf.Chen Wentuo
Guangdong Hospital of Traditional Chinese Medicine Zhuhai HospitalProf.Lin Hao
The Second Affiliated Hospital of Harbin Medical UniversityProf.Li Yongli
The First Affiliated Hospital of Harbin Medical UniversityProf.Shi Huaizhang
The First Hospital of Hebei Medical UniversityProf.Li Conghui
Henan Provincial People's HospitalProf.Li Tianxiao
First Hospital of Jilin UniversityProf.Wang Shouchun
Jinan Central HospitalProf.Zhao Yanxin
Lishui Central HospitalProf.Cai Xueli
Liaocheng Third People's HospitalProf.Song Cunfeng
Linyi City People's HospitalProf.Han Hongxing
The Second Affiliated Hospital of Nanchang UniversityProf.Lai Xianliang
Nanyang City Central HospitalProf.Wen Changming
First Hospital of Shanxi Medical UniversityProf.Zhang Jin
Renji Hospital, Shanghai Jiao Tong University School of MedicineProf.Wan Jieqing
Shanghai Seventh People's HospitalProf.Wang Feng
Xuanwu Hospital, Capital Medical UniversityProf.Jiao Liqun
Wuhan University People's HospitalProf.Ke Wei
Wuhan Central HospitalProf.Jing Ping
The Second Affiliated Hospital of Xi 'an Jiaotong UniversityProf.Zhang Guilian
The First Affiliated Hospital of Xi 'an Jiaotong UniversityProf.Yu Jia
Affiliated Hospital of Southwest Medical UniversityProf.Li Jinglun
Yantai Yuhuangding HospitalProf.Li Bing
Taizhou Hospital of Zhejiang ProvinceProf.Wang En
Chinese People's Liberation Army Eastern Theater Command General HospitalProf.Yin Qin
The Fourth Affiliated Hospital of China Medical UniversityProf.Gao Lianbo
Chinese Academy of Medical Sciences Fuwai HospitalProf.Li Shujuan
Qianjiang Hospital, People's Hospital of Wuhan UniversityProf.Ke Wei

Name of hospital
(In no particular order and in alphabetical order)
Research trends
June 1st
Complete Clinicaltrial Registration
July 4th
Group leader unit through ethics
July 18th
National platform system filing
August 8th
First Branch Center Passed Ethical Review
August 25th
First entry

Enrolled Cases

The number of enrolled cases is counted until April 21, 2024

+8615633140085(Site Manager:Dr.Shengyan Cui)



Xuanwu Hospital, Capital Medical University

45 Chang Chun Street

Xicheng District, Beijing, China

Email:  (Team Manager Dr.Wang Tao)


Cerebral Recanalization Center CHINA-INI(@sss405084186525)